In our previous studies using gene gun-mediated delivery of interleukin 12 (IL-12) cDNA in vivo, we observed T-cell-mediated regression of established murine tumors and demonstrated the induction of systemic immunity in test animals. In this study, we further characterized the antitumoral and anti-metastatic effect of this gene therapy approach by employing two murine metastatic mammary tumor models: the immunogenic TS/A adenocarcinoma and the weakly immunogenic 4T1 adenocarcinoma. In the TS/A model, gene transfer into the skin overlying an established intradermal tumor with an IL-12 cDNA expression vector resulted in complete tumor regression in 50% of mice followed by the development of immunological memory. In contrast, the growth of the intradermal 4T1 tumors was not affected by the IL-12 gene therapy protocol. However, this treatment resulted in a substantial reduction of spontaneous metastases in the lungs of 4T1 tumor-bearing mice and significantly prolonged their survival time. T cells were not required for this anti-metastatic effect, because it was also observed in nude mice and in mice depleted of CD4 ϩ and CD8 
I
nvasive breast cancer is the leading cause of cancer among women and the second most fatal cancer, after lung cancer. 1 Although much progress has been made in the detection and treatment of localized (nonmetastatic) disease, there has been relatively modest progress in the treatment of advanced disease, and Ͼ40,000 women die every year as a result of metastatic breast cancer. 1 There is an urgent need, therefore, to develop new therapeutic approaches for metastatic breast cancer. One such experimental approach is to employ an immunologically based mechanism that could lead to regression of the primary tumor as well as the residual microscopic metastatic foci, and thereby prevent tumor progression or recurrence. In this regard, it has been shown that human breast tumors may express tumor-associated antigens (TAAs) such as HER-2/neu, 2 p53, 3 and MUC-1 4,5 that can be recognized by the immune system. Strategies using cytokines to induce or augment the antitumoral immune response have been proven effective in a variety of animal tumor models. 6 -8 A number of cytokines, including interleukins (ILs) (IL-2, IL-4, IL-6, IL-7, IL-10, and IL-12), interferon-gamma (IFN-␥), and granulocyte-macrophage colony-stimulating factor, have been demonstrated to be effective in augmenting either T-cell-dependent or inflammatory responses that can lead to tumor rejection. 6 -8 Importantly, mice that were challenged with cytokine gene-modified tumor cells often developed long-lasting immunity to unmodified tumor cells. 9 -12 During the past few years, IL-12 has been demonstrated to be one of the most potent antitumoral cytokines in experimental animal models. 13 Specifically, recombinant IL-12 (rIL-12) has been shown to mediate profound T-cell-dependent antitumoral effects in vivo, resulting in regression of established subcutaneous tumors and tumor metastases followed by establishment of tumor-specific immunological memory. 14 -17 However, the dose-dependent toxicity of rIL-12 protein resulting from systemic administration can cause significant clinical complications. 18, 19 An alternative strategy is local delivery of relatively low levels of IL-12 at the tumor site to induce or augment an antitumoral effect without causing systemic toxicity. Indeed, using a gene therapy approach for local IL-12 delivery, we have shown that gene gun-mediated transfer of the IL-12 cDNA expression plasmid into the skin surrounding established tumors results in immunologically mediated tumor regression. 20 In another study, 21 we have shown that IL-12 was clearly superior in terms of antitumoral activity compared with six other cytokines in similar in vivo gene therapy experiments. Furthermore, a significant systemic antitumoral effect of the localized IL-12 gene delivery protocol was demonstrated against distant solid tumors 21 and spontaneous metastases 20 in the immunogenic murine tumor models. Therefore, we hypothesized that an in vivo, localized IL-12 gene therapy procedure delivered at the site of a primary tumor may be a new strategy for the treatment of metastatic breast cancer.
The purpose of this study was to evaluate the antitumoral effects of a gene gun-mediated IL-12 gene therapy protocol in two murine mammary tumor models, the immunogenic TS/A tumor and the putatively nonimmunogenic, but highly metastatic, 4T1 tumor. The experimental design was to achieve, via efficient gene transfer into the skin overlying an established intradermal (i.d.) tumor, sustained secretion of transgenic IL-12 protein locally at the tumor site. We rationalized that this might result in local and then systemic immune activation to an extent sufficient enough to achieve significant tumor regression or suppression of the metastatic spread of tumor cells from the primary tumor into the lungs. In this report, we demonstrate that localized IL-12 gene therapy did indeed result in regression of the immunogenic primary TS/A tumor followed by the development of immunological memory; in anti-metastatic effects were observed against the weakly immunogenic 4T1 tumor. However, in this latter system, the anti-metastatic effect was not mediated by T cells, but seemed to involve natural killer (NK) cells and IFN-␥.
MATERIALS AND METHODS

Mice
BALB/c mice were obtained from Harlan-Sprague-Dawley (Madison, Wis); BALB/c nude mice were supplied by Taconic (Germantown, NY). Female mice between 8 -12 weeks of age were used in the experiments. The housing, care, and use of mice were in accordance with the Guide for Care and Use of Laboratory Animals (National Institutes of Health publication 86-23, National Institutes of Health, Bethesda, Md, 1985) .
Mammary tumor models
The TS/A cell line [22] [23] [24] and the 4T1 cell line 25 were established from spontaneous, moderately differentiated mammary adenocarcinomas growing in BALB/c mice and were kindly provided by G. Forni (Immunogenetic and Histocompatibility Center, Turin, Italy) and F. R. Miller (Michigan Cancer Foundation, Detroit, Mich), respectively. When established as primary subcutaneous tumors, both of these adenocarcinomas metastasize primarily in the lungs. 22, 25 Tumor cell cultures were maintained in RPMI 1640 medium supplemented with 10% fetal bovine sera, 2 mM L-glutamine, and 50 g/mL gentamicin. Before being injected i.d., tumor cells were detached from the plastic by a short incubation in trypsin-ethylenediaminetetraacetic acid solution. Mice were shaved in the abdominal area and injected i.d. with 1 ϫ 10 5 viable tumor cells in 50 L of Dulbecco's phosphate-buffered saline (PBS). Tumor growth was monitored two to three times per week by measuring two perpendicular tumor diameters using calipers. The metastatic tumor load of 4T1 cells was assayed by weighing the excised lungs on day 31 or day 34 after tumor cell implantation, when control tumor-bearing mice became moribund. Alternatively, the survival of mice was monitored after surgical excision of primary tumors on day 11 after tumor cell implantation, as described previously. 20 For most in vivo experiments, eight mice per group were tested; for survival experiments, 12-16 mice per group were evaluated.
Transgene expression vectors
We used the plasmid pWRG3169 containing the coding sequences for the p35 and p40 subunits of murine IL-12, which are arranged in the same orientation in tandem, with each driven by its own cytomegalovirus promoter. 20 This configuration of double-unit gene construction was shown to be more effective in transient gene expression than the use of an internal ribosome entry site sequence or bi-partite plasmid system (our unpublished observations). The luciferase (Luc) cDNA expression vector, which was used as a control, has previously been described elsewhere. 20 
In vivo IL-12 gene transfer
For all in vivo skin transfection experiments, we used a helium-pulse dermal PowderJect-XR device (PowderJect Vaccines, Madison, Wis) as described previously. 20 Briefly, plasmid DNA was precipitated onto gold particles (2.1 m in diameter) and coated onto the inner surface of Tefzel tubing (McMaster-Carr, Chicago, Ill). Each half-inch segment of tubing conferred delivery of 0.5 mg of gold and 1.25 g of plasmid DNA per transfection. For in vivo gene delivery, mouse skin overlying and surrounding the target tumor was transfected with IL-12 cDNA or Luc cDNA expression vectors. Each treatment consisted of four epidermal transfections, totaling 5 g of plasmid DNA/treatment, with a discharge pressure of 300 pounds per square inch helium gas pulse. One transfection was performed directly over the tumor site, and three additional transfections were placed circumferentially at adjacent sites ϳ0.5 cm from the primary tumor site. This gene therapy procedure was performed two to three times per week for 2 weeks.
In vitro studies
Experimental mice were treated with IL-12 cDNA or Luc cDNA on days 7 and 10 after 4T1 tumor cell implantation, and tumor-draining (axillary) lymph nodes (TDLNs) were taken from test mice on day 11. Lymph node cells (1 ϫ 10 6 cells/mL) were incubated in culture medium without any stimuli at 37°C for 48 hours. Cell culture supernatants were collected and frozen at Ϫ20°C until testing. IFN-␥ levels in cell culture supernatants were measured by an enzyme-linked immunosor-bent assay (ELISA) kit (Endogen, Cambridge, Mass). The activity of NK cells was determined in a standard 4-hour 51 Cr release assay using NK-sensitive YAC-1 cells as targets.
In vivo depletion studies
T cells were depleted in mice as described previously. 20 To deplete NK cells, mice were injected via the tail vein with 40 L of anti-asialo GM1 antibody (Ab) (Wako BioProducts, Richmond, Va) diluted in PBS according to the manufacturer's recommendations. Mice received Ab treatments on days 6, 10, and 15 after tumor cell implantation. Control mice received the equivalent dose (1.5 mg/mouse) of rabbit immunoglobulin G (IgG) (Sigma, St. Louis, Mo).
To neutralize IFN-␥, mice were injected intraperitoneally (i.p.) with 0.5 mg anti-IFN-␥ monoclonal Ab (mAb) (R4-6A2), which was obtained from ascites of nude mice injected with the hybridoma cells and enriched for IgG by ammonium sulfate precipitation. Mice were injected with the mAb five times every other day starting 1 day before the commencing of IL-12 or Luc gene delivery. Control mice were injected with 0.5 mg of rat IgG (Sigma). At 0.5 mg/mouse, the anti-IFN-␥ mAb neutralized at least 98% of transgenic IFN-␥ (15 ng/tissue site), which was produced in the skin 24 hours after gene gunmediated skin transfection with IFN-␥ cDNA.
RESULTS
Immunogenicity of TS/A and 4T1 tumors
Because human breast cancer, like most other types of human malignancies, is considered to be poorly immunogenic, 5 we decided to focus our investigation on weakly immunogenic or nonimmunogenic murine breast tumors. TS/A adenocarcinoma has been characterized as nonimmunogenic in some studies 22, 23 and as poorly immunogenic in later studies by the same authors. 24 The 4T1 tumor 25 has not been tested extensively but was found to be rather nonimmunogenic (personal communication from Dr. F. R. Miller, Michigan Cancer Foundation). Therefore, we compared the immunogenicity of these two adenocarcinomas. Flow cytometry analysis revealed that both types of tumor cells express major histocompatibility complex class I antigens; this expression was higher in TS/A cells than in 4T1 cells (data not shown). For vaccination studies, BALB/c mice were immunized i.d. twice in a 3-week interval with 10 6 ␥-irradiated (5000 rad) TS/A or 4T1 adenocarcinoma cells. At 1 month after the last immunization, mice were challenged i.d. with 10 5 viable tumor cells, and tumor growth was followed. The results presented in Figure 1 show that although TS/A tumors did not grow in the vaccinated mice, 4T1 tumors grew in the vaccinated mice at the same rate as in control mice. In separate experiments, some protective effect was observed in the vaccinated mice when a much smaller challenge cell dose (10 4 or 5 ϫ 10 3
4T1 tumor cells) was tested (data not shown). Therefore, our data indicate that TS/A is a relatively immunogenic tumor and that 4T1 is only weakly immunogenic.
Effects of IL-12 gene therapy on the growth of primary TS/A and 4T1 tumors
We subsequently evaluated the antitumoral effect of IL-12 gene therapy against i.d. TS/A and 4T1 tumors after gene gun-mediated skin treatment. Mice were treated according to a standard protocol that we have established previously, 20 starting at day 7 after tumor cell implantation. Figure 2 shows that IL-12 gene therapy resulted in a substantial antitumoral effect against TS/A tumors, in that 50% of treated mice (four of eight mice) rejected established tumors (ϳ0.4 cm in diameter at the time treatment was started). Of the four IL-12-treated mice that had tumors at the end of the experiment, three mice showed the same tumor growth pattern as the Luc-treated mice, whereas one mouse showed apparent rejection of the tumor as measured on day 17, but this tumor reappeared on day 24. This experiment with TS/A tumors was repeated three times, and similar results were obtained. We subsequently found that mice that rejected TS/A tumors remained tumor-free for at least 1 month, resisted a second challenge with the same TS/A tumor cells, and were able to generate an augmented cytotoxic T-lymphocyte response against TS/A tumor cells in vitro (data not shown). In contrast, the growth of the 4T1 primary tumors was not affected by IL-12 gene therapy (Fig 2) . This inability to influence the growth of 4T1 primary tumors by IL-12 gene therapy was observed in seven separate experiments.
Localized IL-12 gene delivery resulted in a systemic anti-metastatic effect against 4T1 tumors 4T1 tumors have been characterized as highly metastatic to lungs and lymph nodes. 25 During our experiments with the therapy of i.d. primary tumors, as described above, we noticed that on day 31 after tumor cell implantation, the Luc cDNA-treated (control) mice looked moribund, whereas the IL-12 cDNA-treated mice did not have visible signs of distress. When the mice were sacrificed and their lungs were inspected, the IL-12-treated mice had a grossly evident decrease in the size of the lungs and the spread of metastatic nodules. Table 1 shows that the average lung weight in IL-12-treated mice was significantly lower than that in Luctreated mice or untreated tumor-bearing mice. The observed effect against spontaneous metastases was further confirmed by two additional criteria: (a) the number of metastatic nodules present in the lungs and (b) the survival time of mice after primary tumor excision. In the first case, mouse skin was transfected with IL-12 cDNA or Luc cDNA on days 7, 10, 14, 17, and 20 after 4T1 tumor cell implantation. Mice were sacrificed on day 21 and immediately injected intratracheally with india ink followed by lung fixation in Fekete's solution as described previously. 26 Mice treated with Luc cDNA (n ϭ 8) had 24.5 Ϯ 3.8 visible tumor nodules, whereas mice treated with IL-12 cDNA (n ϭ 5) had 11.8 Ϯ 1.3 tumor nodules (P Ͻ .01).
For animal survival studies, we first performed an experiment to determine the time course of spontaneous metastasis of 4T1 tumor to the lungs of untreated mice. The primary tumors were surgically removed on day 7, day 11, or day 17 after tumor cell implantation (n ϭ 8 in each group), and the survival time of the mice was assessed. When the tumor was removed on day 7, 62.5% of mice survived for at least 4 months, whereas all mice with the tumors removed on day 11 or day 17 died by day 41 after tumor cell implantation. These results indicate that 4T1 tumor cells metastasize during the first week of tumor growth, and by day 11, virtually all mice develop spontaneous metastases. Therefore, in the following experiments, we excised the primary tumor on day 11 after tumor cell implantation. The results of two independent experiments on mouse survival are presented in Figure 3 . Mice were untreated or transfected with IL-12 cDNA or Luc cDNA into the skin overlying an i.d. tumor on day 3 (experiment 1), or on day 4 (experiment 2), and then on days 7 and 10 after 4T1 tumor cell implantation, followed by tumor excision on day 11. The combined data of two experiments show that 5 of 28 mice (17.85%) treated with IL-12 cDNA survived from spontaneous metastases and were considered "cured," whereas only 1 of 28 mice (3.57%) in each of the two control groups survived until day 120 (observation time). Moreover, analysis of the median survival time of mice that had died during the course of these experiments showed that IL-12-treated mice lived significantly longer than Luctreated mice or untreated mice (48.48 Ϯ 2.43, 40.92 Ϯ 1.52, and 37.14 Ϯ 0.72 days, respectively; P Ͻ .025). All five IL-12 gene-treated mice that survived from metastasis were subsequently challenged with 10 5 4T1 tumor cells, and each of these mice developed tumors at the same rate as naive mice (data not shown).
Anti-metastatic effect of IL-12 gene therapy in T-celldeficient mice
We have shown previously 20, 21 that the regression of immunogenic tumors (such as Renca renal carcinoma and L5178Y lymphoma) induced by the current gene gun-mediated IL-12 gene therapy protocol is dependent upon CD8 ϩ T cells. However, the apparent incapability of 4T1 tumors to induce a strong protective memory immune response, as described above, argued against a critical role of T cells in this tumor model. To directly determine the role of T cells in the observed antimetastatic effect of IL-12 gene therapy, we injected, in a parallel experiment, 4T1 cells i.d. into athymic nude mice as well as into the normal euthymic BALB/c mice. The mice were then treated with our standard IL-12 gene therapy protocol followed by evaluation of lung metastases. Figure 4A shows that IL-12 gene therapy resulted in an anti-metastatic effect in nude mice that was similar to that observed in euthymic mice. In accordance with this result, in vivo depletion of T cells with anti-CD4 and anti-CD8 mAbs did not prevent the ability of IL-12 gene therapy to cause an anti-metastatic effect in euthymic BALB/c mice (Fig 4B) . These data, therefore, suggest that T cells are not required for the anti-metastatic effect observed in the 4T1 tumor model.
Activation of TDLN cells after IL-12 gene therapy
Because T cells do not seem to be required for the observed systemic anti-metastatic effect of IL-12 gene therapy in the 4T1 model, and because IL-12 protein did not exhibit a direct inhibitory effect on the growth of 4T1 tumors in vitro (data not shown), we suggested that administration of IL-12 DNA may have acted by stimulating or augmenting some local or regional, nonspecific defense mechanisms that could suppress the metastasis of 4T1 tumor cells. It has been shown previously that after subcutaneous implantation, 4T1 tumor cells first metastasize into the blood and regional lymph nodes and then into the lungs. 25 We hypothesized, therefore, that localized IL-12 gene therapy near the primary tumor may induce immune or inflammatory reactivity in †Mice were sacrificed on day 31 after tumor cell implantation and lung weight was determined. The lung weight of age-matched naive BALB/c mice was 270 Ϯ 25 mg (n ϭ 4).
TDLNs that in turn could negatively affect tumor growth, invasion, or subsequent spread to the lungs. To test this possibility, we decided to evaluate NK cell activity and IFN-␥ production in TDLN cells after the current IL-12 gene therapy protocol, because it has been reported previously that IL-12 can augment both the cytotoxicity of NK cells 27 and IFN-␥ production. 15, 16, 27, 28 Mice were injected i.d. in the middle of the abdominal Figure 3 . Survival of mice from 4T1 tumor metastases after IL-12 gene therapy followed by excision of a primary tumor. Mice were injected i.d. with 10 5 4T1 tumor cells. Mice were either untreated or treated with IL-12 cDNA or Luc cDNA on days 3 (experiment 1), 4 (experiment 2), 7, and 10 after tumor cell implantation, followed by the excision of the primary tumor on day 11. Survival of the mice was assessed for 120 days. All mice that were alive after 58 days (experiment 1) or 80 days (experiment 2) remained tumor-free for the entire observation period. Data of two independent experiments are presented for 12 (experiment 1) and 16 (experiment 2) mice per group. 5 4T1 tumor cells. Skin was transfected with IL-12 cDNA or Luc cDNA on days 7, 10, 13, and 17 after tumor cell implantation. A mixture containing 300 g of each anti-CD4 mAb (clone GK1.5) and anti-CD8 mAb (clone 2.43) was administered i.p. on days 6, 11, and 16 (experiment 1) or on days 6, 10, 15, and 20 (experiment 2) after tumor cell implantation. Flow cytometric analysis of the peripheral blood cells of these mice, performed 4 days after the last mAb injection, confirmed depletion of 98% of CD3 ϩ cells. Control groups included mice that were treated with IL-12 cDNA and received rat IgG (Sigma) at a dose of 600 g/mouse per day following the same schedule as the anti-CD4/CD8 mAbs, mice treated with Luc cDNA instead of IL-12 cDNA, or non-tumor-bearing naive mice. Lungs were removed on day 31 (experiment 1) or on day 34 (experiment 2), and their weights were determined. Mean lung weights Ϯ SEM are shown for two combined experiments. area with 10 5 4T1 tumor cells and skin-transfected with IL-12 cDNA or Luc cDNA 7 and 10 days later. On day 11, axillary lymph nodes were removed, and the derived cells were either directly assayed for NK cytotoxicity against YAC-1 cells or incubated in vitro without any stimulation at 37°C for 48 hours; next, supernatants were assayed for IFN-␥ by ELISA. Figure 5A shows that although the levels of NK activity were low in TDLNs, possibly due to the low endogenous NK activity in BALB/c mice or because of tumor-induced suppression, the NK activity in the TDLNs of IL-12 gene-treated mice was higher than in control mice. Similarly, the results presented in Figure 5B show that IL-12 gene therapy resulted in a substantially enhanced production of IFN-␥ in TDLNs compared with mice treated with Luc cDNA or untreated tumor-bearing mice. The last experiment was repeated three times, and similar results were obtained. In addition, we have found that recombinant murine IFN-␥ at doses of Ն1 ng/mL can significantly inhibit the proliferation of 4T1 cells in vitro (data not shown).
Role of NK cells and IFN-␥ in the anti-metastatic effect induced by IL-12 gene therapy
Because increased activity of NK cells and an augmented level of IFN-␥ were detected in TDLNs from mice that received IL-12 gene therapy, we subsequently tested whether NK cells or IFN-␥ were involved in the IL-12-induced anti-metastatic effect against 4T1 tumors. To do this, mice received injections of either anti-asialo GM1 Ab or anti-IFN-␥ mAb, respectively, starting 1 day before the treatment with IL-12 and continuing throughout the treatment. The results in Figure 6A show that the anti-metastatic effect of IL-12 gene therapy was slightly reduced in NK cell-depleted mice. Similarly, neutralization of endogenous IFN-␥ in vivo resulted in a lesser suppression of the IL-12-induced anti-metastatic effect in the lungs when compared with the effect of IL-12 in mice that received rat IgG (Fig 6B) .
DISCUSSION
In this study, we show that an in vivo gene therapy protocol with IL-12 cDNA can result in a complete tumor regression of the i.d. injected immunogenic, metastatic murine TS/A adenocarcinoma. In contrast, using the same gene therapy procedure, we found no effect of IL-12 cDNA against the weakly immunogenic, i.d. 4T1 tumor. Remarkably, however, a significant reduction in lung metastases was observed in 4T1 tumor-bearing mice as a result of IL-12 gene therapy.
Understanding tumor immunogenicity is important for the rational design of cancer immunotherapy in humans. The murine tumors used in this study, TS/A and 4T1 mammary adenocarcinomas, were tested for immunogenicity: TS/A tumors were found to be relatively immunogenic, and 4T1 tumors were found to be weakly immunogenic. In two previous studies, TS/A tumors were initially characterized as nonimmunogenic, 22, 23 but later as weakly immunogenic, 24 depending upon the assays used to test immunogenicity. Obviously, it would be helpful if a standardized definition of tumor immunogenicity were applied for experimental cancer immunotherapeutic studies. In many animal studies, a tumor is considered to be immunogenic if it induces, after either surgical excision or vaccination, immune-mediated protection against a secondary challenge of the same tumor in vivo. 29 However, the ability to protect against a tumor may largely depend upon the dosage and design of the immunization or tumor challenge. 24 In the present study, we show that when 10 5 4T1 tumor cells were used for a challenge, the protective effect of vaccination was not detected (Fig 1) . However, the 4T1 tumor, which would be classified as "nonimmunogenic" based on these data, is rather "weakly immunogenic," 5 4T1 tumor cells. On days 7 and 10 after tumor cell implantation, the skin overlying the tumor was transfected with 5 g of IL-12 cDNA or Luc cDNA or left untreated. On day 11 after tumor cell implantation, axillary lymph nodes were removed, pooled from three mice per group, and tested for cytotoxicity against NK-sensitive YAC-1 cells in a 4-hour 51 Cr assay. Results are expressed as the cytotoxic index at an effector to target ratio of 100:1. B: One million of the same lymphoid cells were placed in 1 mL of medium for 48 hours. The activity of IFN-␥ in the supernatants was determined by ELISA. Both graphs depict means Ϯ SEM for two cell samples per group; each sample contained TDLN cells pooled from three mice. 5 4T1 tumor cells. On days 7, 10, 13, and 17 after tumor cell implantation, the skin overlying the tumor was transfected with 5 g of IL-12 cDNA or Luc cDNA or left untreated. On days 6, 10, and 15 after tumor cell implantation, mice treated with IL-12 were injected via the tail vein with 40 L of anti-asialo GM1 Ab or with 1.5 mg of rabbit IgG in 200 L of PBS. Mice were sacrificed on day 33-36 after tumor cell implantation; next, lungs were removed and their weight was determined. The mean Ϯ SEM of three independent combined experiments is shown; n ϭ 15-21 mice per group. P Ͻ .025 represents a significant difference between the IL-12 ϩ rabbit IgG-treated group and the nontreated group as well as the difference between the IL-12 ϩ rabbit IgG-treated group and the Luc-treated group. The difference between the IL-12 ϩ rabbit IgG-treated group and the IL-12 ϩ anti-asialo GM1 Ab group was not statistically significant. B: Mice were injected i.d. with 10 5 4T1 tumor cells. Because in this experiment tumors were developing at a slower rate than usually observed, initiation of gene therapy was delayed until day 11 and continued on days 14, 17, and 21 after tumor cell implantation. Mice treated with IL-12 cDNA or Luc cDNA were injected i.p. with 0.5 mg of anti-IFN-␥ mAb (R4-6A2) or with 0.5 mg of rat IgG on days 10, 12, 14, 16, and 18 after tumor cell implantation. Lungs were removed on day 39 after tumor cell implantation, and their weight was determined. Results of a single experiment are shown as lung weights in milligrams (mean Ϯ SEM of three to four mice per group). P ϭ .005 represents a significant difference between the IL-12 ϩ rat IgG-treated group and the Luc ϩ rat IgG-treated group. P Ͼ .1 indicates no statistical difference between the IL-12 ϩ anti-IFN-␥ mAb-treated group and the Luc ϩ anti-IFN-␥ mAb-treated group.
because a low level of immune response could be detected when Յ10 4 tumor cells were used for challenge. Most human tumors have previously been considered nonimmunogenic because of their spontaneous origin and because of the difficulties encountered in documenting T-cell reactivity to autologous tumors. Therefore, the immunogenic murine tumor models employed for immunotherapy studies have been considered by some researchers to be invalid models for translation into clinical applications. 29, 30 However, recent progress in tumor and cellular immunology research has provided good evidence that many human tumors may in fact be immunogenic, as defined by their expression of TAAs that can be recognized by autologous T lymphocytes. 31, 32 For instance, for human breast tumors, the most characterized TAAs are HER-2/neu, 2 p53, 3 and DF3/MUC-1. 4, 5 Moreover, it has been shown that these Ags could induce cytotoxic T-cell responses in some patients. 5, 33 As a result, immunotherapeutic strategies for the treatment of metastatic breast cancers have recently received increased attention. One approach for cancer immunotherapy involves the use of recombinant cytokines for the purpose of boosting the existing antitumoral immune response. Studies in animal models have shown that IL-12, compared with other cytokines, can confer strong antitumoral efficacy, 21, 28, 34 likely as a result of its known immune stimulation effects on T helper 1 cells, cytotoxic T cells, and NK cells. 35 Based on these studies, clinical trials with IL-12 were initiated. However, substantial dose-dependent toxicity was induced by the initial clinical use of rIL-12 protein. 19 Although the lack of a predosing schedule was suggested as a cause for this toxicity, 36 these experiments have suggested the benefit of exploring alternative IL-12 delivery mechanisms to devise treatments that are both safe and effective. Using an IL-12 gene therapy approach in mice, we have shown that localized in vivo IL-12 gene transfer into skin tissue can result in the eradication of certain established murine tumors and their metastases, leading to the generation of a strong tumor-specific immunological memory. 20 No signs of IL-12 toxicity were observed after this gene gun-mediated therapy protocol. 37 In this study, we extend our findings by showing that two murine mammary tumors are susceptible to IL-12 gene therapy. For approximately half of the animals, a complete tumor regression was achieved in the TS/A tumor model followed by generation of immunological memory, which is similar to the findings we reported previously with other immunogenic tumors. 20 It is not clear why IL-12-treated TS/A tumor-bearing mice segregated into complete responders and essentially nonresponders; however, this phenomenon is not unique for TS/A tumors, as a similar response pattern is occasionally observed in different tumor models. 38 An experimental answer to this question could definitely be of theoretical value and clinical importance. In contrast to TS/A tumors, the growth of an i.d. injected localized 4T1 tumor was not affected by the same gene therapy protocol. It was found, however, that although the growth of the primary 4T1 tumor was not suppressed by IL-12 gene therapy, the degree of metastasis in the lungs was significantly reduced. These data imply that lack of a therapeutic effect on the primary solid tumor does not necessarily mean the absence of an antitumoral effect. In addition, we show in this study that, in contrast to the T-cell-dependent antitumoral effect of our IL-12 gene therapy approach against immunogenic tumors, 20 the anti-metastatic effect against the weakly immunogenic 4T1 tumor does not appear to be mediated by T cells. This is different from previously published results indicating that the antitumoral or anti-metastatic effects of rIL-12 protein 14 -16 or IL-12 cDNA 39, 40 were primarily mediated by T cells. Our results with the 4T1 tumor model are consistent with certain studies using gene therapy strategies with IL-2 41 and IL-4, 42 which showed that some antitumoral responses involved macrophages and polymorphonuclear leukocytes and apparently did not involve T cells. Polymorphonuclear leukocytes were also reported to be involved in IL-12-induced antitumoral effects; however, these cells were found to be important in defense against primary solid tumors rather than spontaneous lung metastases. 43 The mechanism of the anti-metastatic effect of IL-12 gene therapy in the 4T1 tumor model is not clear at this time. It appears that T-cell activities are not required, because the anti-metastatic effect was also observed in T-cell-deficient mice. Knowing that 4T1 cells can metastasize from a subcutaneous deposit into lungs and other organs through blood and TDLNs, 25 we hypothesized that certain local or regional cellular processes, induced by the IL-12 gene therapy, may be responsible for the reduction of tumor metastasis into the lungs. Indeed, we show that augmented activity of NK cells and increased levels of IFN-␥ in TDLNs can be readily demonstrated after IL-12 gene therapy. Moreover, we found that in vivo depletion of NK cells with anti-asialo GM1 Ab or neutralization of IFN-␥ with anti-IFN-␥ mAb resulted in a partial (although not statistically significant in the case of NK cells) inhibition of the anti-metastatic effect. Our data are in agreement with the findings of others showing that NK cells can be activated by IL-12 27, 44 and mediate anti-metastatic effects in some tumor models. 45 Although NK cells could play a role in early protection against IL-12 gene-transfected tumors, 39 the regression of established tumors induced by IL-12 therapy is reportedly mediated by T cells 14, 15, 20 and does not require NK cells. 14 The results of this study suggest that activated NK cells may be involved in IL-12-induced defense against established, weakly immunogenic tumors, possibly via the killing of endothelial cell targets, as has been reported recently. 46 The results of this study also agree with the data of others showing that IFN-␥ is induced by IL-12 15, 16, 27, 28, 47 and can mediate, at least in part, the antitumoral effect of IL-12. 15, 16, 28 In contrast to IL-12, IFN-␥ can confer direct cytotoxicity to tumor cells in vitro. 28 We also observed that recombinant murine IFN-␥ was cytotoxic to 4T1 cells in vitro, whereas rIL-12 was not. It is not clear, however, whether direct cytotoxicity of NK cells or IFN-␥ in TDLNs can account for the observed anti-metastatic effect against 4T1 tumors in vivo. However, our results suggest that the immune activation in TDLNs induced by IL-12 gene therapy may restrict or inhibit tumor metastasis from the primary tumor site into the lungs.
In addition to its immunological functions, IL-12 has been shown to inhibit angiogenesis. 48, 49 The antiangiogenic effect of IL-12 has been suggested as an important antitumoral mechanism, especially in Tcell-deficient mice. 48, 50, 51 In vivo neutralization of IFN-␥ or depletion of NK cells resulted in almost complete inhibition of IL-12-induced anti-angiogenic effects in several models. 46, 48, 50 These Ab treatments were also able to partially inhibit the IL-12-induced, anti-metastatic effect in our experiments (Fig 6) , suggesting that there may be an anti-angiogenic mechanism of the IL-12 gene therapy protocol. However, the lack of suppression of i.d. 4T1 tumors (Fig 2) compared with the profound tumor growth suppression due to the anti-angiogenic abilities of IL-12 in other tumor models 46, 48 indicates that IL-12 gene therapy did not induce an anti-angiogenic effect strong enough to suppress the growth of the primary 4T1 tumors. Another possible explanation of the observed anti-metastatic effect of IL-12 gene therapy is that the anti-angiogenic effect of IL-12 was exhibited preferentially against the more extensively neovascularized metastatic tumor in the lungs. However, the systemic levels of biologically active IL-12 induced by our IL-12 gene therapy protocol were shown to be below our assay detection limit (Ͻ100 pg/mL) 20 and therefore seem unlikely to induce a strong systemic anti-angiogenic effect. Thus, gene gun-mediated IL-12 gene therapy, in contrast to rIL-12 protein, failed to induce several systemic immune and pathophysiological effects. 37 Although it is not yet clear whether delivery of IL-12 cDNA at the tumor site is important for induction of the observed anti-metastatic effect, delivery of IL-12 cDNA in a skin site distant from the site of an implanted immunogenic tumor failed to induce tumor regression, whereas treatment with IL-12 cDNA at skin overlying the tumor site was highly therapeutic. 21 Therefore, the anti-angiogenic effect of IL-12 may not entirely account for the observed anti-metastatic effect of IL-12 gene therapy against the 4T1 tumor.
It is not clear whether the observed anti-metastatic effect in the lungs is due solely to the effect of locally expressed IL-12 protein resulting from the IL-12 gene therapy or due also to the mode of IL-12 delivery via epidermal gene transfection. For example, it seems possible that such a slow, continuous release of localized, transgenic IL-12 protein can result in the activation of regional immunity or inflammation in a different way than that from the injection of rIL-12 protein into tissue, which could rapidly diffuse under in vivo conditions. Nevertheless, we suggest, based on this study and previous studies, 20, 37 that the gene gun-mediated in vivo IL-12 gene therapy approach may be developed further as an effective and safe alternative to the systemic delivery of rIL-12 protein for cancer therapy. The TS/A and 4T1 mammary tumor cell lines used in this study and the different antitumoral effects of IL-12 gene therapy on primary tumors versus visceral metastases may provide a highly desirable experimental model for immunotherapy and gene therapy studies related to human breast cancer. We believe that extension of this study may provide an experimental rationale for proceeding with future clinical testing of gene gun-mediated IL-12 gene therapy for breast cancer.
